Personalized Acromegaly Treatment Platform
Legal Citation
Summary of the Inventive Concept
A next-generation system integrating AI, bioinformatics, and precision medicine to optimize acromegaly treatment outcomes, enhancing patient quality of life and reducing healthcare costs.
Background and Problem Solved
The original patent for oral drug delivery of octreotide addressed a significant need in acromegaly treatment. However, it had limitations in terms of individualized treatment regimens, dosage optimization, and real-time biomarker feedback. The present inventive concept overcomes these limitations by leveraging cutting-edge technologies to create a personalized treatment platform.
Detailed Description of the Inventive Concept
The inventive concept comprises a bioinformatics module analyzing genomic data and medical history to predict optimal treatment regimens. An AI-powered dosage optimization module adjusts octreotide administration schedules based on real-time biomarker feedback from wearable devices or nanoparticle-based formulations. This enables precision medicine-based acromegaly management, where customized octreotide formulations and dosages are tailored to individual receptor profiles and disease severity.
Novelty and Inventive Step
The new claims introduce a paradigm shift in acromegaly treatment by integrating AI, bioinformatics, and precision medicine. The inventive concept's novelty lies in its ability to provide personalized treatment regimens, real-time biomarker feedback, and optimized dosage administration, which are not addressed by the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include integrating additional data sources, such as electronic health records or medical imaging, to further enhance treatment personalization. Variations may involve using different AI algorithms or machine learning models to optimize dosage administration.
Potential Commercial Applications and Market
The personalized acromegaly treatment platform has significant commercial potential in the pharmaceutical and healthcare industries, offering a competitive advantage in the treatment of rare diseases. The market for precision medicine-based treatments is growing rapidly, and this inventive concept is poised to capitalize on this trend.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/08 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K9/4858 |
| A | A61 | A61K38/31 |
| A | A61 | A61P5/06 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, focusing on peptide drug delivery, endocrinology, and precision medicine technologies for hormonal disorders
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with expertise in drug formulation, biotechnology, AI-driven medical technologies, and advanced drug delivery systems, holding advanced degrees and practical experience in developing targeted therapeutic interventions
Obviousness Rationale
A PHOSITA would recognize that the PTD's AI-powered personalization and advanced delivery mechanisms represent predictable technological extensions of the source patent's oral octreotide treatment methodology. The disclosed variations leverage known computational and pharmaceutical engineering techniques to enhance treatment precision and patient outcomes. These modifications represent incremental improvements using standard interdisciplinary approaches in precision medicine and drug delivery technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,595 |
|---|---|
| Title | Method of treating diseases |
| Assignee(s) | Amryt Endo, Inc. |